For years, health technology assessment in Europe has been fragmented, with each country applying its own criteria and timelines. A system that ensured autonomy, but also led to duplication and unequal access to care.
The HTA Regulation (EU 2021/2282) aims to address this fragmentation by introducing a common framework for clinical evaluation. From 2025, a new model begins to take shape, designed to coordinate Member States.
But this is not just a technical adjustment.
It is a shift in how value in healthcare is defined.
From fragmentation to convergence
At the core of the regulation are the Joint Clinical Assessments (JCAs)—shared evaluations at the European level focusing on clinical effectiveness and safety.
The goal is clear: avoid repeating the same assessments across countries.
Yet convergence remains partial.
Pricing and reimbursement decisions stay at the national level, as do healthcare priorities. This creates a delicate balance between European alignment and local autonomy.
The real turning point: evidence
The HTA Regulation fundamentally shifts the system’s center of gravity:
regulatory approval is no longer enough—what matters is comparative clinical value.
JCAs do not determine price, but assess how a technology performs against existing alternatives.
For companies, this means:
- designing studies with relevant comparators
- stronger alignment with the PICO framework
- increasing use of real-world evidence
It is no longer sufficient to prove that a product works.
It must be shown why it works better—and for whom.
A strategic impact
The impact of the Regulation goes beyond processes.
It reshapes strategy.
On one side, it reduces duplication.
On the other, it raises the bar: a single clinical assessment with implications across multiple markets.
This leads to:
- greater importance of early planning
- reduced flexibility for country-specific strategies
- increased exposure to evidence-related risk
A weak clinical assessment at the European level can affect multiple national markets simultaneously.
Implementation challenges
Like any systemic reform, the HTA Regulation brings uncertainties:
- operational capacity of national HTA bodies
- real methodological alignment
- differences in clinical comparators across countries
- integration between EU-level assessments and national decisions
Its success will depend less on the regulation itself and more on how it is implemented in practice.
A balance still in the making
European HTA does not centralize decisions—it coordinates them.
It does not eliminate differences—it attempts to manage them.
It represents a balancing act between:
- innovation and sustainability
- scientific evidence and policy decisions
- European coordination and national responsibility
A balance that is still evolving.
Why the EIPG report matters
In this context, the report by the European Industrial Pharmacists Group offers one of the first insights into the real-world implementation of the HTA Regulation.
It moves beyond theory, exploring:
- how systems are adapting
- what challenges are emerging
- what role pharmaceutical professionals will play
This is where regulation becomes reality.
👉 The following article presents the EIPG analysis on the implementation of the HTA Regulation.
